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Summary
Metabolic syndrome and nephrolithiasis are quite common
disorders presenting similar epidemiological characteristics.
Belonging to genetic, environmental and hormonal interac-
tion, they have high incidence and prevalence in the adult
population of industrialised countries and are characterised
by a high level of morbidity and mortality if not adequately
identified and treated. Despite metabolic syndrome is consid-
ered a fundamental risk factor for chronic kidney diseases, is
not actually known whether it is associated with nephrolithia-
sis beyond the effect of its individual components, in particu-
lar obesity, glucose intolerance, and hypertension. In this pa-
per, the possible pathogenetic links between metabolic syn-
drome and nephrolithiasis will be presented and discussed.
KEY WORDS: metabolic syndrome, nephrolithiasis, insulin resistance, vita-
min D, gender, dietary habits.
Introduction
In recent years, some scientific panels proposed to introduce
the metabolic syndrome into clinical practice as a multidimen-
sional risk condition for cardiovascular morbidity and mortality
(1-5). Despite different definitions of metabolic syndrome
have been proposed, there is general consensus regarding
its main components: obesity, hypertension and disorders of
carbohydrate and lipid metabolism [i.e., elevated serum
triglyceride and apolipoprotein B (apoB), increased small LDL
particles, and a reduced level of HDL cholesterol (HDL-C)].
Individuals with these characteristics commonly harbor a pro-
inflammatory state, resulting in a pro-thrombotic condition.
Along with many other chronic syndromes and diseases,
metabolic syndrome belong to a multi-factorial origin and its
pathogenesis can be classified into underlying causes and
exacerbating factors (6, 7). The predominant underlying risk
factors for the syndrome appear to be abdominal obesity and
insulin-resistance. Other metabolic syndrome components
could be considered exacerbating factors having a direct ef-
fect on atherosclerotic disease (6, 7). An atherogenic diet
(e.g., a diet rich in saturated fat and cholesterol) can enhance
risk for developing cardiovascular disease in people with the
syndrome, although this diet is not listed specifically as an
underlying risk factor for the condition  (4). Physical inactivity,
aging, and hormonal imbalance could be also considered as
risk factors for the development of the metabolic syndrome
(8-11). Screening programs for obesity and its complications
would be justified if earlier intervention were shown to clearly
reduce morbidity and mortality. Several systematic reviews
have examined the evidence regarding the benefits, limita-
tions and cost-effectiveness of a broad range of clinical pre-
ventive services for obesity.
Recent studies indicate metabolic syndrome as pivotal risk fac-
tor for chronic kidney diseases (12, 13). In the past few years,
some of the metabolic syndrome components have been also
associated with the occurrence of nephrolithiasis or with bio-
chemical abnormalities which in turn are related to kidney
stone disease (14-23), but is not actually known whether meta-
bolic syndrome itself is associated with nephrolithiasis beyond
the effect of its individual components. In this paper, the possi-
ble pathogenetic links between metabolic syndrome and
nephrolithiasis will be discussed.
Epidemiology
Metabolic syndrome and nephrolithiasis present similar epi-
demiological characteristics. Both are caused by the interaction
of genetic, environmental and hormonal factors, present a high
incidence and prevalence in the adult population of industri-
alised countries and are characterised by a high level of mor-
bidity and mortality if not adequately identified and treated (8,
10, 24). In particular, in Italy the prevalence of metabolic syn-
drome increases dramatically with age, from about 3% among
people in their 20s to over 25% among people older than 70
years. Application of estimated prevalence data to the Italian
adult population, suggests that more than 6 million individuals
may have the metabolic syndrome, about 3.6 million women
and 3 million men (25). On the other hand, at least 5% of Ital-
ians aged over 35 years of age have had a symptomatic
episode of kidney stones, more than 100,000 admissions are
recorded every year due to renal colic for an overall cost of
over 200,000 million euro, and at least 3500 cases of chronic
renal failure each year are secondary to nephrolithiasis (26).
Finally, In the latter part of the 20th century both diseases
showed an increased prevalence and incidence in adult women
(27, 28).
Epidemiological preliminary data indicate that metabolic syn-
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drome is a risk factor for nephrolithiasis in both gender. In this
regard, in a hospital-based survey performed in Southern Italy,
we found a significant association between metabolic syn-
drome and echographic evidence of nephrolithiasis (29).
Insulin-resistance and obesity
A first common pathogenetic background between metabolic
syndrome and nephrolithiasis could be identified in the pres-
ence of insulin-resistance. As previously reported, insulin-re-
sistance plays a crucial role in the initiation and maintenance
of the various clinical features of metabolic syndrome (6, 7)
and also significantly influences the urinary salts supersatura-
tion (19, 30, 31). Kidney stone formation results from a phase
change in which urinary dissolved salts condense into solids,
and all phase changes are driven by salts supersaturation,
which is usually approximated by the ratio of the urinary salt
concentration to its solubility and is calculated by computer
algorithms (24). In addition to urine volume, calcium and ox-
alate concentrations are the main determinants of calcium ox-
alate urine supersaturation. Urine calcium concentration and
pH are the main determinants of calcium phosphate supersat-
uration and urinary pH is the main determinant of uric acid
supersaturation (24). Insulin-resistance directly influences uri-
nary salts supersaturation by affecting urinary pH as well as
calcium, phosphate, urate and citrate excretion (19, 30, 31).
A clinical condition tightly intertwined with insulin-resistance is
obesity. Obesity causes insulin-resistance, and conversely,
inherent forms of insulin-resistance modify adipose tissue re-
sponses to insulin and thereby recapitulate the obese state
(6, 7, 32-34). Previous studies indicate that obesity was asso-
ciated with greater risk of kidney stones disease (15, 22, 35,
36). Obesity and weight gain significantly influence calcium-
oxalate and calcium-phosphate urine supersaturation acting
on urinary pH as well as urinary calcium, phosphate and
urate excretion (15, 22, 35, 36).
Vitamin D biological system, insulin-resistance and
nephrolithiasis
Experimental studies also indicate the vitamin D biological sys-
tem could play a role in the pathogenesis of both nephrolithia-
sis and insulin-resistance. Vitamin D endocrine system regu-
lates multiple aspects of calcium and bone metabolism, includ-
ing calcium absorption and excretion, but also plays an impor-
tant role in glucose homeostasis, notably in the mechanism of
insulin release (37-40). Vitamin D may have a beneficial effect
on insulin action either directly, by stimulating the expression of
insulin receptor, thereby enhancing insulin responsiveness for
glucose transport (41), or indirectly via its role in regulating ex-
tracellular calcium ensuring normal calcium influx through cell
membranes and adequate intracellular cytosolic ionized calci-
um pool (42, 43). Biological actions of vitamin D are mediated
by the binding of 1,25(OH)2D3 to a specific cytosolic/nuclear vit-
amin D receptor (VDR), a member of the steroid/thyroid hor-
mone receptor superfamily and a vitamin D response elements
(VDREs) has been detected in the human insulin receptor
gene promoter (44-46).
Several frequent polymorphisms are found in the VDR gene
and were reported to be associated with a variety of physiologi-
cal and pathological phenotypes in many populations including
the occurrence of insulin-resistance in diabetic type 2 patients
as well as of idiopathic hypercalciuria and hypocitraturia in re-
current stone forming patients (47-54).
Influence of gender: the role of estrogen production
The magnitude of association between obesity and kidney
stone disease varies by gender, with a stronger influence in
women (21). The fall of estrogen production significantly influ-
ences the emergence of metabolic syndrome in post-
menopausal women by increasing body mass index and vis-
ceral fat accumulation (11). On the other hand, ovarian failure
significantly increases bone turnover and urinary calcium ex-
cretion and, at the same time, reduces the excretion of in-
hibitors of urinary crystal nucleation and growth (i.e., citrate)
(55-57).
These data indicate that menopause and ovarian failure could
be another pathogenic link between kidney stone disease and
metabolic syndrome in women and could explain the increased
prevalence of kidney stone disease observed in the last years
in women (27, 28).
Dietary habits, metabolic syndrome, hypertension and
nephrolithiasis
Changes in dietary habits and lifestyle contribute markedly to
the rise in the prevalence and incidence of kidney stone dis-
ease as well as obesity, hypertension and metabolic syndrome
(4, 58-60). The human diet before the Industrial Revolution was
characterized by a large intake of fresh fruits and vegetables
which guaranteed a large intake of potassium (100-200
mmol/day) (61). These foods rich in potassium were are also
usually rich in HCO3-yielding precursors like citrate, and virtu-
ally no contain sodium. Conversely, the modern diet, which
dates 200 years ago, is characterized by an higher content of
sodium and chloride and a significantly lower content of potas-
sium and HCO3-yielding substances (62). Indeed, the potassi-
um/sodium and HCO3/chloride ratios have become reversed
with the advent of the modern diet while the renal physiological
properties remain largely unchanged, genetically fixed in Pale-
olithic time. Thus, the electrolytic mix of the modern diet is pro-
foundly mismatched to its genetically determined processing
machinery, and the extent of this diet-kidney mismatch increas-
es with age, largely because the contemporary dietary intake of
potassium decreases with age, as recently demonstrated in
Caucasian-Americans and African-Americans cohorts (63). Re-
nal sodium and calcium transports are close coupled and
changes in tubular sodium handling directly affect urinary calci-
um excretion (64). In the kidney, sodium-dependent calcium re-
absorption occurs in the proximal tubule, that is responsible for
~60% of calcium reabsorption by passive paracellular diffusion,
and in the thick ascending loop. In the distal tubule, calcium re-
absorption is primarily through the TRPV5 channel, expression
of which is increased by parathyroid hormone and 1,25-dihy-
droxy vitamin D (65). Increased sodium intake increases uri-
nary calcium excretion in humans; every increase of dietary
sodium of 100 mmol (6 g of sodium chloride) causes an in-
crease in urinary calcium excretion of 1 mmol (66, 67). This ef-
fect occurs in both calcium stone formers with hypercalciuria as
well as in normal, non-stone forming adults (68, 69). Bicarbon-
ate and organic anions such as citrate, but not chloride, miti-
gate the effect of increased dietary sodium intake increasing
the urinary pH (70). Urinary alkalinization increase directly the
renal calcium reabsorption and reduce also the calcium release
from bone (71). Considering that an high dietary sodium is typi-
cal in obese patients, an increased sodium dietary intake is an-
other possible link between kidney stone disease and metabol-
ic syndrome (35, 70).
Diets rich in animal protein is considered an important determi-
nant for occurrence of metabolic syndrome, but is also a risk
factor for nephrolithiasis. In effect, this diet makes urine more
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lithogenic by increasing uric acid and calcium excretion and de-
creasing citrate excretion and urinary pH (72-80). On the other
hand, a statistical association between hypertension and
nephrolithiasis in both cross-sectional and prospective epi-
demiological investigations has been reported by our group
and by others (14, 16, 17, 81-83). As renal tubular calcium
handling may be altered in hypertensive patients, leading to in-
creased urinary calcium excretion (84), hypercalciuria seems a
plausible pathogenetic link between the two conditions in sub-
jects who carry genetic susceptibility and possibly other risk
factors for nephrolithiasis (85).
References
11. Alberti KG, Zimmet PZ. Definition, diagnosis and classification of
diabetes mellitus and its complications, part 1: diagnosis and clas-
sification of diabetes mellitus provisional report of a WHO consul-
tation. Diabet Med. 1998;15:539-53. 
12. Clinical Guidelines on the Identification, Evaluation, and Treatment
of Overweight and Obesity in Adults–the Evidence Report. Nation-
al Institutes of Health. Obes Res. 1998;6 (suppl 2):51S-209S.
13. Balkau B, Charles MA. Comment on the provisional report from
the WHO consultation. European Group for the Study of Insulin
Resistance (EGIR). Diabet Med. 1999;16:442-3.
14. National Cholesterol Education Program (NCEP) Expert Panel on
Detection, Evaluation, and Treatment of High Blood Cholesterol in
Adults (Adult Treatment Panel III). Third Report of the National
Cholesterol Education Program (NCEP) Expert Panel on Detec-
tion, Evaluation, and Treatment of High Blood Cholesterol in
Adults (Adult Treatment Panel III) final report. Circulation. 2002;
106:3143-421.
15. Grundy SM, Cleeman JI, Daniels SR, et al. Diagnosis and man-
agement of the metabolic syndrome: an American Heart Associa-
tion/National Heart, Lung, and Blood Institute Scientific Statement.
Circulation. 2005;112:2735-52.
16. Grundy SM. Does the metabolic syndrome exist? Diabetes Care.
2006;29:1689-692.
17. Grundy SM. Metabolic syndrome: a multiplex cardiovascular risk
factor. J Clin Endocrinol Metab. 2007;92:399-404. 
18. Park YW, Zhu S, Palaniappan L, et al. The metabolic syndrome:
prevalence and associated risk factor findings in the US popula-
tion from the Third National Health and Nutrition Examination Sur-
vey, 1988-1994. Arch Intern Med. 2003;163:427-36.
19. Gustat J, Srinivasan SR, Elkasabany A, et al. Relation of self-rat-
ed measures of physical activity to multiple risk factors of insulin
resistance syndrome in young adults: the Bogalusa Heart Study. J
Clin Epidemiol. 2002;55:997-1006.
10. Ford ES, Giles WH, Dietz WH. Prevalence of the metabolic syn-
drome among US adults: findings from the Third National Health
and Nutrition Examination Survey. JAMA. 2002;287:356-9.
11. Carr MC. The emergence of the metabolic syndrome with
menopause. J Clin Endocrinol Metab. 2003;88:2404-11.
12. Locatelli F, Pozzoni P, Del Vecchio L. Renal manifestations in the
metabolic syndrome. J Am Soc Nephrol. 2006;17:S81-S85. 
13. Chen J, Muntner P, Hamm LL, et al. The metabolic syndrome and
chronic kidney disease in U.S. adults. Ann Intern Med. 2004;140:
167-174.
14. Cappuccio FP, Strazzullo P, Mancini M. Kidney stones and hyper-
tension: an independent clinical association in a population-based
study. BMJ. 1990;300:1234-6. 
15. Curhan GC, Willett WC, Rimm EB, et al. Body size and risk of kid-
ney stones. J Am Soc Nephrol. 1998;9:1645-52.
16. Borghi L, Meschi T, Guerra A, et al. Essential arterial hypertension
and stone disease. Kidney Int. 1999;55:2397-406.
17. Strazzullo P, Barba G, Vuotto P, et al. Past history of nephrolithia-
sis and incidence of hypertension in men: a reappraisal based on
the results of the Olivetti Prospective Heart Study. Nephrol Dial
Transplant. 2001;16:2232-5. 
18. Tisler A, Pierratos A, Honey JD, et al. High urinary excretion of
uric acid combined with high excretion of calcium links kidney
stone disease to familial hypertension. Nephrol Dial Transplant.
2002;17:253-9. 
19. Abate N, Chandalia M, Cabo-Chan AV Jr, et al. The metabolic
syndrome and uric acid nephrolithiasis: novel features of renal
manifestation of insulin resistance. Kidney Int. 2004;65:386-92. 
20. Taylor EN, Stampfer MJ, Curhan GC. Diabetes mellitus and the
risk of nephrolithiasis. Kidney Int. 2005;68:1230-5. 
21. Gillen DL, Coe FL, Worcester EM. Nephrolithiasis and increased
blood pressure among females with high body mass index. Am J
Kidney Dis. 2005;46:263-9. 
22. Taylor EN, Stampfer MJ, Curhan GC. Obesity, weight gain, and
the risk of kidney stones. JAMA. 2005;93:455-62.
23. Taylor EN, Mount DB, Forman JP, et al. Association of prevalent
hypertension with 24-hour urinary excretion of calcium, citrate, and
other factors. Am J Kidney Dis. 2006;47:780-9. 
24. Coe FL, Evan A, Worcester E. Kidney stone disease. J Clin Invest.
2005;115:2598-608.
25. Miccoli R, Bianchi C, Odoguardi L, et al. Prevalence of the meta-
bolic syndrome among Italian adults according to ATP III defini-
tion. Nutr Metab Cardiovasc Dis. 2005;15:250-4.
26. Serio A, Fraioli A. Epidemiology of nephrolithiasis. Nephron.
1999;81(suppl 1):26.
27. Scales CD Jr, Curtis LH, Norris RD, et al. Changing gender preva-
lence of stone disease. J Urol. 2007;177:979-82.
28. Lieske JC, Pena de la Vega LS, Slezak JM, et al. Renal stone epi-
demiology in Rochester, Minnesota: an update. Kidney Int. 2006;
69:760-4.
29. Mossetti G, Rendina D, De Filippo G, et al. Relationship between
metabolic syndrome and nephrolithiasis in a cohort of caucasian
subjects from southern Italy. Clin Case Miner Bone Metab. 2006;
3(3):386-7.
30. Schwille PO, Schmiedt A, Herrmann U. Post prandial hyperinsuli-
naemia, insulin resistance and inappropriately high phosphaturia
are features of younger males with idiopathic calcium urolithiasis:
attenuation by ascorbicacid supplementation of a test meal. Urol
Res. 1997;25:45-9.
31. Cupisti A, Meola M, D'Alessandro C, et al. Insulin resistance and
low urinary citrate excretion in calcium stone formers. Biomed
Pharmacother. 2007;61:86-90.
32. Berg AH, Scherer PE. Adipose tissue, inflammation, and cardio-
vascular disease. Circ Res. 2005;96:939-49.
33. Abate N, Chandalia M, Snell PG, et al. Adipose tissue metabolites
and insulin resistance in nondiabetic Asian Indian men. J Clin En-
docrinol Metab. 2004;89:2750-5.
34. Yusuf S, Hawken S, Ounpuu S, et al. Obesity and the risk of my-
ocardial infarction in 27,000 participants from 52 countries: a case-
control study. Lancet. 2005;366:1640-9. 
35. Taylor EN, Curhan GC. Body size and 24-hour urine composition.
Am J Kidney Dis. 2006;48(6):905-15.
36. Maalouf NM, Sakhaee K, Parks JH, et al. Association of urinary
pH with body weight in nephrolithiasis. Kidney Int. 2004;65(4):
1422-5.
37. Dusso AS, Brown AJ, Slatopolsky E. Vitamin D. Am J Physiol Re-
nal Physiol. 2005;289:F8-F28.
38. Pittas AG, Lau J, Hu FB, et al. The role of vitamin D and calcium
in type 2 diabetes. A systematic review and meta-analysis. J Clin
Endocrinol Metab. 2007;92(6):2017-29. 
39. Reis AF, Hauache OM, Velho G. Vitamin D endocrine system and
the genetic susceptibility to diabetes, obesity and vascular dis-
ease. A review of evidence. Diabetes Metab. 2005;31:318-25.
40. Kerstetter J, Caballero B, O’Brien K, et al. Mineral homeostasis in
obesity: Effects of euglycemic hyperinsulinemia. Metabolism.
1991;40:707-13.
41. Maestro B, Campion J, Davila N, et al. Stimulation by 1,25-dihy-
droxyvitamin D3 of insulin receptor expression and insulin respon-
siveness for glucose transport in U-937 human promonocytic cells.
Endocr J. 2000;47:383-391.
42. Draznin B, Sussman K, Kao M, et al. The existence of an optimal
range of cytosolic free calcium for insulin-stimulated glucose trans-
port in rat adipocytes. J Biol Chem. 1987;262:14385-8.
©
 
IC
 
DI
ZI
ON
I I
NT
E
NA
ZI
ON
AL
I
Clinical Cases in Mineral and Bone Metabolism 2008; 5(2): 114-117 117
Metabolic syndrome and nephrolithiasis
43. Draznin B, Sussman KE, Eckel RH, et al. Possible role of cytosolic
free calcium concentrations in mediating insulin resistance of obe-
sity and hyperinsulinemia. J Clin Invest. 1988;82:1848-52.
44. Haussler MR, Whitfield GK, Haussler CA, et al. The nuclear vita-
min D receptor: biological and molecular regulatory properties re-
vealed. J Bone Miner Res. 1998;13:325-49.
45. Norman AW. Minireview: vitamin D receptor: new assignments for
an already busy receptor. Endocrinology. 2006;147(12):5542-8. 
46. Maestro B, Dávila N, Carranza MC, et al. Identification of a Vita-
min D response element in the human insulin receptor gene pro-
moter. J Steroid Biochem Mol Biol. 2003;84(2-3):223-30.
47. Uitterlinden AG, Fang Y, Van Meurs JB, et al. Genetics and biolo-
gy of vitamin D receptor polymorphisms. Gene. 2004;338:143-56. 
48. Valdivielso JM, Fernandez E. Vitamin D receptor polymorphisms
and diseases. Clin Chim Acta. 2006;371:1-12.
49. Rendina D, Mossetti G, Viceconti R, et al. Association between vit-
amin D receptor gene polymorphisms and fasting idiopathic hyper-
calciuria in recurrent stone-forming patients. Urology. 2004;64:
833-8.
50. Mossetti G, Rendina D, Viceconti R, et al. The relationship of 3' vi-
tamin D receptor haplotypes to urinary supersaturation of calcium
oxalate salts and to age at onset and familial prevalence of
nephrolithiasis. Nephrol Dial Transplant. 2004;19:2259-65.
51. Mossetti G, Vuotto P, Rendina D, et al. Association between vita-
min D receptor gene polymorphisms and tubular citrate handling in
calcium nephrolithiasis. J Intern Med. 2003;253:194-200.
52. Oh JY, Barrett-Connor E. Association between vitamin D receptor
polymorphism and type 2 diabetes or metabolic syndrome in com-
munity-dwelling older adults: the Rancho Bernardo Study. Metabo-
lism. 2002;51(3):356-9.
53. Ye WZ, Reis AF, Dubois-Laforgue D, Bellanné-Chantelot C, Timsit
J, Velho G. Vitamin D receptor gene polymorphisms are associat-
ed with obesity in type 2 diabetic subjects with early age of onset.
Eur J Endocrinol. 2001;145(2):181-6.
54. Reis AF, Hauache OM, Velho G. Vitamin D endocrine system and
the genetic susceptibility to diabetes, obesity and vascular disease.
A review of evidence. Diabetes Metab. 2005;31(4 Pt 1):318-25. 
55. Bergsland KJ, Kinder J, Asplin JR, et al. Influence of gender and
age on calcium oxalate crystal growth inhibition by urine from rela-
tives of stone forming patients. J Urol. 2002;167:2372-76.
56. Kato Y, Yamaguchi S, Kakizaki H, et al. Influence of estrus status
on urinary chemical parameters related to urolithiasis. Urol Res.
2005;33:476-80. 
57. Heller HJ, Sakhaee K, Moe OW, et al. Etiological role of estrogen
status in renal stone formation. J Urol. 2002;168:1923-7.
58. Siener R. Impact of dietary habits on stone incidence. Urol Res.
2006;34(2):131-3.
59. Khaw K-T, Barrett-Connor E. The association between blood pres-
sure, age, and dietary sodium and potassium: a population study.
Circulation. 1988;77:53-61. 
60. Cirillo M, Laurenzi M, Panarelli W, et al. Urinary sodium to potassi-
um ratio and urinary stone disease. Kidney Int. 1994;46:1133-9.
61. Morris RC Jr, Schmidlin O, Frassetto LA, et al. Relationship and
interaction between sodium and potassium. J Am Coll Nutr. 2006;
25(3 Suppl):262S-70S.
62. Eaton SB, Konner M. Paleolithic nutrition. A consideration of its
nature and current implications. N Engl J Med. 1985;312:283-9.
63. Frisancho AR, Leonard WR, Bollettino LA. Blood pressure in
blacks and whites and its relationship to dietary sodium and potas-
sium intake. J Chron Dis. 1984;37:515-9.
64. Friedman PA. Codependence of renal calcium and sodium trans-
port. Annu Rev Physiol. 1998; 60:179-97. 
65. Hoenderop JG, van der Kemp AW, Hartog A, et al. Molecular
identification of the apical Ca2+ channel in 1,25-dihydroxyvitamin
D3-responsive epithelia. J Biol Chem. 1999;274:8375-8.
66. Blackwood AM, Sagnella GA, Cook DG, et al. Urinary calcium ex-
cretion, sodium intake and blood pressure in a multi-ethnic popula-
tion: results of the Wandsworth Heart and Stroke Study. J Hum
Hypertens. 2001;15:229-37.
67. Cirillo M, Ciacci C, Laurenzi M, et al. Salt intake, urinary sodium,
and hypercalciuria. Miner Electrolyte Metab. 1997;23:265-8.
68. Sakhaee K, Harvey JA, Padalino PK, et al. The potential role of
salt abuse on the risk for kidney stone formation. J Urol. 1993;
150:310-2.
69. Timio F, Kerry SM, Anson KM, et al. Calcium urolithiasis, blood
pressure and salt intake. Blood Press. 2003;12:122-7.
70. Obligado SH, Goldfarb DS. The association of nephrolithiasis
with hypertension and obesity: a review. Am J Hypertens. 2008,
doi:10.1038/ajh.2007.62.
71. Lemann J Jr, Bushinsky DA, Hamm LL. Bone buffering of acid and
base in humans. Am J Physiol Renal Physiol. 2003;285:F811-32. 
72. Meschi T, Maggiore U, Fiaccadori E, et al. The effect of fruits and
vegetables on urinary stone risk factors. Kidney Int. 2004;66:
2402-10.
73. Allen LH, Oddoye EA, Margen S. Protein-induced hypercalciuria: a
longer term study. Am J Clin Nutr. 1979;32:741-9. 
74. Hegsted M, Linkswiler HM. Long-term effects of level of protein in-
take on calcium metabolism in young adult women. J Nutr. 1981;
111:244-51. 
75. Zemel MB, Schuette SA, Hegsted M, et al. Role of the sulfur-con-
taining amino acids in protein-induced hypercalciuria in men. J Nu-
tr. 1981;111:545-52. 
76. Linkswiler HM, Zemel MB, Hegsted M, et al. Protein-induced hy-
percalciuria. Fed Proc. 1981;40:2429-33.
77. Lemann J Jr, Gray RW, Maierhofer WJ, et al. The importance of
renal net acid excretion as a determinant of fasting urinary calcium
excretion. Kidney Int. 1986;29:743-6. 
78. Breslau NA, Brinkley L, Hill KD, et al. Relationship of animal pro-
tein-rich diet to kidney stone formation and calcium metabolism. J
Clin Endocrinol Metab. 1988;66:140-6. 
79. Reddy ST, Wang CY, Sakhaee K, et al. Effect of low-carbohydrate
high-protein diets on acid-base balance, stone-forming propensity,
and calcium metabolism. Am J Kidney Dis. 2002;40:265-74. 
80. Hiatt RA, Ettinger B, Caan B, et al. Randomized controlled trial of
a low animal protein, high fiber diet in the prevention of recurrent
calcium oxalate kidney stones. Am J Epidemiol. 1996;144:25-33.
81. Cirillo M, Laurenzi M. Elevated blood pressure and positive history
of kidney stones: results from a population-based study. J Hyper-
tens. 1988;6:S485- 6. 
82. Madore F, Stampfer MJ, Rimm EB, et al. Nephrolithiasis and risk
of hypertension. Am J Hypertens. 1998;11:46-53. 
83. Cappuccio FP, Siani A, Barba G, et al. A prospective study of hy-
pertension and the incidence of kidney stones in men. J Hyper-
tens. 1999;17:1017-22. 
84. Strazzullo P, Galletti F, Cirillo M, et al. Altered extracellular calci-
um homoeostasis in essential hypertension: a consequence of ab-
normal cell calcium handling. Clin Sci (Lond). 1986;71:239-44.
85. Mente A, Honey RJ, McLaughlin JM, et al. High urinary calcium
excretion and genetic susceptibility to hypertension and kidney
stone disease. J Am Soc Nephrol. 2006;17:2567-75.
©
 C
IC
 E
DI
ZI
ON
I I
NT
ER
NA
ZI
ON
AL
I
